Davos Alzheimer's Collaborative Healthcare System Preparedness to Increase Cognitive Assessment Rates for Older Adults
Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Dec 20, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Davos Alzheimer's Collaborative Healthcare System trial is exploring ways to improve how we screen older adults for cognitive issues, such as memory problems related to conditions like Alzheimer’s disease. The researchers want to find out which combination of questionnaires, digital tests, and blood tests works best to help doctors in community settings identify those who may need further evaluation for cognitive decline.
To participate in this study, you need to be 65 years or older. If you join, you can expect to answer some questions and possibly take digital tests related to your memory and thinking skills. The goal is to make it easier for healthcare providers to spot cognitive decline early, so that individuals can receive the appropriate care and support. If you're interested and meet the age requirement, this could be a valuable opportunity to contribute to important research in Alzheimer's care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age 65 years or older
- Exclusion Criteria:
- • younger than 65 years
About Ludwig Maximilians University Of Munich
Ludwig-Maximilians-University of Munich (LMU Munich) is a prestigious research institution in Germany, renowned for its commitment to advancing medical science and improving patient care through innovative clinical research. As a leading sponsor of clinical trials, LMU Munich leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous studies aimed at evaluating new therapeutic interventions and advancing healthcare knowledge. The university fosters collaboration among researchers, clinicians, and healthcare professionals, ensuring that trials are designed and executed with the highest ethical standards and scientific integrity. Through its dedication to excellence in research, LMU Munich aims to contribute significantly to the development of effective treatments and enhance the overall health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
München, Bayern, Germany
Patients applied
Trial Officials
Robert Perneczky, Prof. Dr.
Principal Investigator
Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported